Prospective Grant of Exclusive License: Development of a ME-TARP Based Immunotherapy, 59798-59799 [2015-24989]

Download as PDF 59798 Federal Register / Vol. 80, No. 191 / Friday, October 2, 2015 / Notices Dated: September 28, 2015. Richard U. Rodriguez, Acting Director, Office of Technology Transfer, National Institutes of Health. published under the publication rules of either the United States Patent and Trademark Office or the World Intellectual Property Organization. [FR Doc. 2015–24982 Filed 10–1–15; 8:45 am] DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Prospective Grant of Exclusive License: Analytical Instruments Utilizing Condensation Particle Counters for the Detection and Analysis of Small Aerosol Particles Public Health Service, National Institutes of Health, HHS. ACTION: Notice. AGENCY: This is notice, in accordance with 35 U.S.C. 209 and 37 CFR part 404, that the Public Health Service, Department of Health and Human Services, is contemplating the grant of an exclusive license to Kanomax Japan, Inc. having a principal place of business in Osaka, Japan, to practice the inventions embodied in U.S. Provisional Patent Application No. 62/026,559, filed on 18 July 2014, entitled ‘‘Aerosol Particle Growth Systems for Personal Sampling Applications Using Polymer Electrolyte Membranes’’ [HHS Reference No. E–026–2014/0–US–01]. The patent rights in these inventions have been assigned to the United States of America. The territory of the prospective exclusive patent license may be worldwide, and the field of use may be limited to ‘‘Analytical instruments comprising condensation particle counters (CPCs) for the sampling, detection, counting and analysis of ultrafine and nano-sized aerosol particles.’’ DATES: Only written comments and/or applications for a license that are received by the NIH Office of Technology Transfer on or before November 2, 2015 will be considered. ADDRESSES: Requests for a copy of the patent application, inquiries, comments and other materials relating to the contemplated license should be directed to: Tara L. Kirby, Ph.D., Chief, CDC Unit, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852–3804; Telephone: (301) 435–4426; Facsimile: (301) 402– 0220; Email: tarak@mail.nih.gov. A signed confidential disclosure agreement may be required to receive copies of the patent application assuming it has not already been mstockstill on DSK4VPTVN1PROD with NOTICES VerDate Sep<11>2014 20:43 Oct 01, 2015 Jkt 238001 Hazardous airborne particles pose a risk for health and safety in a variety of environments and thus detection of these small particles is essential. Current particle magnification systems are bulky and require a lot of power for operation, making them unsuitable to easily detect and analyze small particles in mobile and personal settings. The CDC has developed space-saving miniature instrumentation and methods for the direct sampling and analysis of small particles (diameter <300–400 nm). The systems can effectively sample air at a rate of a few liters per minute and concentrate the particulate matter into microliter or milliliter liquid samples. The novel system uses proton exchange membranes to grow small particles for optical detection using standard methods. Further, these methods allow the system to separate condensation and aerosol flow to enhance user mobility. Moreover, the described methods use inexpensive materials and require low power for operation. The prospective exclusive license will be royalty bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR part 404. The prospective exclusive license may be granted unless, within thirty (30) days from the date of this published notice, the NIH Office of Technology Transfer receives written evidence and argument that establishes that the grant of the contemplated license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR part 404. Properly filed competing applications for a license in the prospective field of use that are filed in response to this notice will be treated as objections to the contemplated license. Comments and objections submitted in response to this notice will not be made available for public inspection, and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552. Prospective Grant of Exclusive License: Development of a ME–TARP Based Immunotherapy SUPPLEMENTARY INFORMATION: BILLING CODE 4140–01–P SUMMARY: DEPARTMENT OF HEALTH AND HUMAN SERVICES Dated: September 28, 2015. Richard U. Rodriguez, Acting Director, Office of Technology Transfer, National Institutes of Health. [FR Doc. 2015–24985 Filed 10–1–15; 8:45 am] BILLING CODE 4140–01–P PO 00000 Frm 00079 Fmt 4703 Sfmt 4703 National Institutes of Health AGENCY: National Institutes of Health, HHS. ACTION: Notice. This is notice, in accordance with 35 U.S.C. 209 and 37 CFR 404.7, that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent license to practice the inventions embodied in the following U.S. Patents and Patent Applications to PDS Biotechnology Corporation (‘‘PDS’’) located in New Brunswick, New Jersey, USA: SUMMARY: Intellectual Property 1. United States Provisional Patent Application No. 60/476,467, filed June 5, 2003, entitled ‘‘Immunogenic Peptides and Peptide Derivatives For The Treatment of Prostate And Breast Cancer Treatment’’ [HHS Reference No. E–116– 2003/0–US–01]; 2. International Patent Application No. PCT/ US2004/17574 filed June 2, 2004 entitled ‘‘Immunogenic Peptides And Peptide Derivatives For The Treatment of Prostate And Breast Cancer Treatment’’ [HHS Reference No. E–116–2003/0– PCT–02]; 3. United States Patent No.7,541,035, issued June 2, 2009, entitled ‘‘Immunogenic Peptides And Peptide Derivatives For The Treatment of Prostate And Breast Cancer Treatment’’ [HHS Reference No. E–116–2003/0–US–03]; 4. United States Patent No. 8,043,623, issued 25 Oct 2011, entitled ‘‘Immunogenic Peptides and Peptide Derivatives For The Treatment of Prostate And Breast Cancer Treatment’’ [HHS Reference No. E–116–2003/0–US–04]; 5. United States Provisional Patent Application No. 61/915,948, filed December 13, 2013, entitled ‘‘MultiEpitope TARP Peptide Vaccine and Uses Thereof’’ [HHS Reference No. E–047– 2014/0–US–01]; 6. International Patent Application No. PCT/ US2014/070144 filed December 12, 2014 entitled ‘‘Multi-Epitope TARP Peptide Vaccine and Uses Thereof’’ [HHS Reference No. E–047–2014/0–PCT–02]; and all continuation applications, divisional applications and foreign counterpart applications claiming priority to the US provisional application no. 61/915, 948. The patent rights in these inventions have been assigned to the government of the United States of America. The prospective exclusive license territory may be worldwide and the E:\FR\FM\02OCN1.SGM 02OCN1 Federal Register / Vol. 80, No. 191 / Friday, October 2, 2015 / Notices field of use will be limited to the use of Licensed Patent Rights for the following Fields of Use: and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552. 1. Development and Commercialization of an ME–TARP-based therapy containing at least one cationic lipid within the scope of the Licensed Patent Rights. 2. Development and Commercialization of a cell based therapeutic product with ME– TARP for Prostate Cancer. Dated: September 28, 2015. Richard U. Rodriguez, Acting Director, Office of Technology Transfer, National Institutes of Health. Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before November 2, 2015 will be considered. ADDRESSES: Requests for copies of the patent application, inquiries, and comments relating to the contemplated exclusive license should be directed to: Sabarni K. Chatterjee, Ph.D., M.B.A. Senior Licensing and Patenting Manager, NCI Technology Transfer Center, 9609 Medical Center Drive, RM 1E530 MSC 9702, Bethesda, MD 20892– 9702 (for business mail), Rockville, MD 20850–9702; Telephone: (240) 276– 5530; Facsimile: (240) 276–5504; Email: chatterjeesa@mail.nih.gov. SUPPLEMENTARY INFORMATION: This invention concerns the identification of immunogenic peptides within TARP, and their use to create an anti-cancer immune response in patients. By introducing these peptides into a patient, an immune response against these cancer cells can be initiated by the peptides, resulting in treatment of the cancer. A phase I clinical trial in stage D0 prostate cancer patients is nearing completion. Initial results indicate a statistically significant decrease in the slope of PSA for 48 weeks after vaccination. The technology has the potential of being developed into a vaccine for various cancer indications or for the treatment of any cancer associated with increased or preferential expression of TARP. The prospective exclusive license will be royalty bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless within thirty (30) days from the date of this published notice, the NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7. Complete applications for a license in the field of use filed in response to this notice will be treated as objections to the grant of the contemplated exclusive license. Comments and objections submitted to this notice will not be made available for public inspection [FR Doc. 2015–24989 Filed 10–1–15; 8:45 am] BILLING CODE 4140–01–P mstockstill on DSK4VPTVN1PROD with NOTICES DATES: VerDate Sep<11>2014 20:43 Oct 01, 2015 Jkt 238001 DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Center for Scientific Review; Notice of Closed Meetings Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: Center for Scientific Review Special Emphasis Panel; Fellowships: Neurodevelopment, Synaptic Plasticity and Neurodegeneration. Date: October 22–23, 2015. Time: 8:00 a.m. to 6:00 p.m. Agenda: To review and evaluate grant applications. Place: The Embassy Row Hotel, 2015 Massachusetts Avenue NW., Washington, DC 20036. Contact Person: Mary Schueler, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5214, MSC 7846, Bethesda, MD 20892, 301–451– 0996, marygs@csr.nih.gov. Name of Committee: Biobehavioral and Behavioral Processes Integrated Review Group; Biobehavioral Regulation, Learning and Ethology Study Section. Date: October 29–30, 2015. Time: 8:30 a.m. to 6:00 p.m. Agenda: To review and evaluate grant applications. Place: Renaissance New Orleans Arts Hotel, 700 Tchoupitouls Street, New Orleans, LA 70130. Contact Person: Mark D. Lindner, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3182, MSC 7770, Bethesda, MD 20892, 301–435– 0913, lindnermd@csr.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; Member PO 00000 Frm 00080 Fmt 4703 Sfmt 4703 59799 Conflict: Surgical Science and Bioengineering. Date: October 29, 2015. Time: 11:00 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (Virtual Meeting). Contact Person: John Firrell, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5118, MSC 7854, Bethesda, MD 20892, 301–435– 2598, firrellj@csr.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; Member Conflict: Medical Imaging Investigations. Date: October 29, 2015. Time: 11:45 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (Virtual Meeting). Contact Person: Mehrdad Mohseni, MD, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5211, MSC 7854, Bethesda, MD 20892, 301–435– 0484, mohsenim@csr.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; RFA Panel: Molecular Probes. Date: October 30, 2015. Time: 8:00 a.m. to 2:00 p.m. Agenda: To review and evaluate grant applications. Place: Beacon Hotel and Corporate Quarters, 1615 Rhode Island Avenue NW., Washington, DC 20036. Contact Person: Mary Custer, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4148, MSC 7850, Bethesda, MD 20892, (301) 435– 1164, custerm@csr.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; Member Conflict: Brain Injury and Neuro-cognitive Impairment. Date: October 30, 2015. Time: 1:00 p.m. to 3:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (Telephone Conference Call). Contact Person: Alexander Yakovlev, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5206, MSC 7846, Bethesda, MD 20892–7846, 301– 435–1254, yakovleva@csr.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; PAR13– 309–311: Translational Research in Pediatric and Obstetric, Pharmacology and Therapeutics. Date: October 30, 2015. Time: 1:00 p.m. to 4:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (Telephone Conference Call). E:\FR\FM\02OCN1.SGM 02OCN1

Agencies

[Federal Register Volume 80, Number 191 (Friday, October 2, 2015)]
[Notices]
[Pages 59798-59799]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2015-24989]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Prospective Grant of Exclusive License: Development of a ME-TARP 
Based Immunotherapy

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This is notice, in accordance with 35 U.S.C. 209 and 37 CFR 
404.7, that the National Institutes of Health, Department of Health and 
Human Services, is contemplating the grant of an exclusive patent 
license to practice the inventions embodied in the following U.S. 
Patents and Patent Applications to PDS Biotechnology Corporation 
(``PDS'') located in New Brunswick, New Jersey, USA:

Intellectual Property

1. United States Provisional Patent Application No. 60/476,467, 
filed June 5, 2003, entitled ``Immunogenic Peptides and Peptide 
Derivatives For The Treatment of Prostate And Breast Cancer 
Treatment'' [HHS Reference No. E-116-2003/0-US-01];
2. International Patent Application No. PCT/US2004/17574 filed June 
2, 2004 entitled ``Immunogenic Peptides And Peptide Derivatives For 
The Treatment of Prostate And Breast Cancer Treatment'' [HHS 
Reference No. E-116-2003/0-PCT-02];
3. United States Patent No.7,541,035, issued June 2, 2009, entitled 
``Immunogenic Peptides And Peptide Derivatives For The Treatment of 
Prostate And Breast Cancer Treatment'' [HHS Reference No. E-116-
2003/0-US-03];
4. United States Patent No. 8,043,623, issued 25 Oct 2011, entitled 
``Immunogenic Peptides and Peptide Derivatives For The Treatment of 
Prostate And Breast Cancer Treatment'' [HHS Reference No. E-116-
2003/0-US-04];
5. United States Provisional Patent Application No. 61/915,948, 
filed December 13, 2013, entitled ``Multi-Epitope TARP Peptide 
Vaccine and Uses Thereof'' [HHS Reference No. E-047-2014/0-US-01];
6. International Patent Application No. PCT/US2014/070144 filed 
December 12, 2014 entitled ``Multi-Epitope TARP Peptide Vaccine and 
Uses Thereof'' [HHS Reference No. E-047-2014/0-PCT-02]; and all 
continuation applications, divisional applications and foreign 
counterpart applications claiming priority to the US provisional 
application no. 61/915, 948.

    The patent rights in these inventions have been assigned to the 
government of the United States of America.
    The prospective exclusive license territory may be worldwide and 
the

[[Page 59799]]

field of use will be limited to the use of Licensed Patent Rights for 
the following Fields of Use:

1. Development and Commercialization of an ME-TARP-based therapy 
containing at least one cationic lipid within the scope of the 
Licensed Patent Rights.
2. Development and Commercialization of a cell based therapeutic 
product with ME-TARP for Prostate Cancer.

DATES: Only written comments and/or applications for a license which 
are received by the NIH Office of Technology Transfer on or before 
November 2, 2015 will be considered.

ADDRESSES: Requests for copies of the patent application, inquiries, 
and comments relating to the contemplated exclusive license should be 
directed to: Sabarni K. Chatterjee, Ph.D., M.B.A. Senior Licensing and 
Patenting Manager, NCI Technology Transfer Center, 9609 Medical Center 
Drive, RM 1E530 MSC 9702, Bethesda, MD 20892-9702 (for business mail), 
Rockville, MD 20850-9702; Telephone: (240) 276-5530; Facsimile: (240) 
276-5504; Email: chatterjeesa@mail.nih.gov.

SUPPLEMENTARY INFORMATION: This invention concerns the identification 
of immunogenic peptides within TARP, and their use to create an anti-
cancer immune response in patients. By introducing these peptides into 
a patient, an immune response against these cancer cells can be 
initiated by the peptides, resulting in treatment of the cancer. A 
phase I clinical trial in stage D0 prostate cancer patients is nearing 
completion. Initial results indicate a statistically significant 
decrease in the slope of PSA for 48 weeks after vaccination.
    The technology has the potential of being developed into a vaccine 
for various cancer indications or for the treatment of any cancer 
associated with increased or preferential expression of TARP.
    The prospective exclusive license will be royalty bearing and will 
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. 
The prospective exclusive license may be granted unless within thirty 
(30) days from the date of this published notice, the NIH receives 
written evidence and argument that establishes that the grant of the 
license would not be consistent with the requirements of 35 U.S.C. 209 
and 37 CFR 404.7.
    Complete applications for a license in the field of use filed in 
response to this notice will be treated as objections to the grant of 
the contemplated exclusive license. Comments and objections submitted 
to this notice will not be made available for public inspection and, to 
the extent permitted by law, will not be released under the Freedom of 
Information Act, 5 U.S.C. 552.

    Dated: September 28, 2015.
Richard U. Rodriguez,
Acting Director, Office of Technology Transfer, National Institutes of 
Health.
[FR Doc. 2015-24989 Filed 10-1-15; 8:45 am]
 BILLING CODE 4140-01-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.